LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

NextCure, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERNXTC
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / NXTC COVERAGE

What’s moving NextCure, Inc. now

Current reporting with the operating signal separated from the noise.

01
NextCure, Inc. Presents Promising Preclinical Data for NC605 in Osteogenesis Imperfecta at Brittle Bone Society Meeting

NextCure, Inc. Presents Promising Preclinical Data for NC605 in Osteogenesis Imperfecta at Brittle Bone Society Meeting

The story matters when it changes NextCure, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
NextCure, Inc. (2US.MU)

NextCure, Inc. (2US.MU)

The story matters when it changes NextCure, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
NextCure, Inc. Doses First Patient in Phase 1 Study of B7-H4-Targeting Antibody-Drug Conjugate LNCB74

NextCure, Inc. Doses First Patient in Phase 1 Study of B7-H4-Targeting Antibody-Drug Conjugate LNCB74

The story matters when it changes NextCure, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade

NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade

The story matters when it changes NextCure, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
With 37% ownership, NextCure, Inc. (NASDAQ:NXTC) has piqued the interest of institutional investors

With 37% ownership, NextCure, Inc. (NASDAQ:NXTC) has piqued the interest of institutional investors

The story matters when it changes NextCure, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to ...

ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to ...

The story matters when it changes NextCure, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest NXTC filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-05 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-05 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-14 · Period 2026-07-14SEC ↗8-KMaterial company eventFiled 2026-06-25 · Period 2026-06-18SEC ↗8-KMaterial company eventFiled 2026-06-01 · Period 2026-06-01SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-24 · Period 2026-06-18SEC ↗4Official SEC filingFiled 2026-08-03 · Period 2026-07-30SEC ↗
EARNINGS / QUARTERLY TRACKER

NextCure, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.